BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 7, 2020
View Archived Issues
Myelin regulatory factor helps out pancreatic cancer cells
Read More
Angiotensin inhibitors for AD prevention
Read More
Phase II study of mavrilimumab in giant cell arteritis meets efficacy endpoints
Read More
Chiba Prefecture patents new compounds targeting mitochondrial DNA mutations
Read More
Cortexyme discloses Porphyromonas gingivalis RgpB inhibitors
Read More
University of Maryland synthesizes new Mcl-1 and Bcl-2 dual inhibitors
Read More
Inflammatory response gene identified in sepsis
Read More
Anlotinib plus pemetrexed beneficial in platinum-resistant epithelial ovarian cancer
Read More
University of California identifies new EGFR inhibitors
Read More
Early clinical data presented for rebastinib
Read More
Fulcrum Therapeutics discovers new EED inhibitors
Read More
Nivolumab + cabozantinib in first-line RCC: CheckMate 9ER suggests new standard of care
Read More
Phase I data presented for Sym-021 as monotherapy or in combination with Sym-022 or Sym-023
Read More
Gut-derived LEAP2 fragment demonstrates beneficial metabolic effects on RYGB
Read More
Activity seen in phase Ib study of sintilimab and niraparib in advanced solid tumors
Read More
Zenith Epigenetics signs CRADA with NCI to develop ZEN-3694 for cancer
Read More
Amgen reports topline phase II results with sotorasib in KRAS G12C-mutant advanced NSCLC
Read More
Phase II study of neflamapimod for dementia with Lewy bodies meets primary endpoint
Read More
NexImmune initiates phase I/II trial of NEXI-002 in multiple myeloma
Read More
Avrobio licenses gene therapy for Hunter's syndrome from University of Manchester
Read More
Eureka Therapeutics begins phase I/II trial of T-cell therapy in HCC
Read More
Pharmacokinetic data on AbFero's iron chelator SP-420 support planned phase I/II study
Read More